Developing biomarker arrays predicting sleep and circadian-coupled risks to health

Sleep

Volumn 39, Issue 4, 2016, Pages 727-736

  Mullington, Janet M ^a   Abbott, Sabra M ^b   Carroll, Judith E ^c   Davis, Christopher J ^d   Dijk, Derk Jan ^e   Dinges, David F ^f   Gehrman, Philip R ^g   Ginsburg, Geoffrey S ^h   Gozal, David ⁱ   Haack, Monika ^a   Lim, Diane C ^g   Macrea, Madalina ^j,k   Pack, Allan I ^l   Plante, David T ^m   Teske, Jennifer A ⁿ   Zee, Phyllis C ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF SURREY   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k UNIVERSITY OF VIRGINIA   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m Section of Allergy   (United States)

ⁿ UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MELATONIN; MESSENGER RNA; NEUROTRANSMITTER; NEUROTROPHIN; TRANSCRIPTOME;

ALERTNESS; ARTICLE; BIOSENSOR; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; DAYTIME SOMNOLENCE; DEPRESSION; DIABETES MELLITUS; GENE SEQUENCE; GOLD STANDARD; HEALTH CARE COST; HEALTH HAZARD; HEART PROTECTION; HUMAN; INNATE IMMUNITY; ISCHEMIC PRECONDITIONING; LIPID HOMEOSTASIS; LIPIDOMICS; METABOLIC DISORDER; METABOLOMICS; MULTICHANNEL RECORDER; NATIONAL HEALTH ORGANIZATION; NUCLEAR MAGNETIC RESONANCE; OBESITY; PHENOTYPE; PHYSICAL EXAMINATION; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROTEOMICS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SLEEP; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP PATTERN; SLEEP WAKING CYCLE; WORK SCHEDULE;

EID: 84962476806     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.5616     Document Type: Article

References (89)

1. Gozal D. Serum, urine, and breath-related biomarkers in the diagnosis of obstructive sleep apnea in children: Is it for real? Curr Opin Pulmonary Med 2012; 18: 561-7.
2. Wong TK. The search on an ideal disease marker for childhood obstructive sleep apnea syndrome. Sleep 2011; 34: 133-4.
3. Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: Dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003; 26: 117-26.
4. Van Dongen HP, Baynard MD, Maislin G, Dinges DF. Systematic interindividual differences in neurobehavioral impairment from sleep loss: Evidence of trait-like differential vulnerability. Sleep 2004; 27: 423-33.
5. Van Dongen HPA, Maislin G, Dinges DF. Dealing with interindividual differences in the temporal dynamics of fatigue and performance: Importance and techniques. Aviat Space Environ Med 2004; 75: A147-54.
6. Kuna ST, Maislin G, Pack FM, et al. Heritability of performance deficit accumulation during acute sleep deprivation in twins. Sleep 2012; 35: 1223-33.
7. Chandler JF, Arnold RD, Phillips JB, Turnmire AE. Predicting individual differences in response to sleep loss: Application of current techniques. Aviat Space Environ Med 2013; 84: 927-37.
8. Watson NF, Badr M, Belenky G, et al. Recommended amount of sleep for a healthy adult: A joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep 2015; 38: 843-4.
9. Gangwisch JE. A review of evidence for the link between sleep duration and hypertension. Am J Hypertens 2014; 27: 1235-42.
10. Gangwisch JE, Malaspina D, Posner K, et al. Insomnia and sleep duration as mediators of the relationship between depression and hypertension incidence. Am J Hypertens 2010; 23: 62-9.
11. Mullington JM, Haack M, Toth M, Serrador J, Meier-Ewert HK. Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Progr Cardiovasc Dis 2009; 51: 294-302.
12. Parthasarathy S, Vasquez MM, Halonen M, et al. Persistent insomnia is associated with mortality risk. Am J Med 2015; 128: 268-75.
13. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: A novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol 2005; 99: 2008-19.
14. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Metaanalysis of quantitative sleep parameters from childhood to old age in healthy individuals: Developing normative sleep values across the human lifespan. Sleep 2004; 27: 1255-73.
15. Chen JC, Espeland MA, Brunner RL, et al. Sleep duration, cognitive decline, and dementia risk in older women. Alzheimers Dement 2016; 12: 21-33.
16. Mullington JM, Simpson NS, Meier-Ewert HK, Haack M. Sleep loss and inflammation. Best Pract Res Clin Endocrinol Metab 2010; 24: 775-84.
17. Shearer WT, Reuben JM, Mullington JM, et al. Soluble TNF-A receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 2001; 107: 165-70.
18. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999; 84: 2603-7.
19. Irwin MR, Wang MG, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 2006; 166: 1756-62.
20. Irwin MR, Witarama T, Caudill M, Olmstead R, Breen EC. Sleep loss activates cellular inflammation and signal transducer and activator of transcription (STAT) family proteins in humans. Brain Behav Immun 2015; 47: 86-92.
21. Dimitrov S, Lange T, Benedict C, et al. Sleep enhances IL-6 transsignaling in humans. FASEB J 2006; 20: 2174-6.
22. Frey DJ, Fleshner M, Wright KP Jr. The effects of 40 hours of total sleep deprivation on inflammatory markers in healthy young adults. Brain Behav Immun 2007; 21: 1050-7.
23. Thimgan MS, Gottschalk L, Toedebusch C, et al. Cross-translational studies in human and drosophila identify markers of sleep loss. Plos One 2013; 8: E61016.
24. Faraut B, Nakib S, Drogou C, et al. Napping reverses the salivary interleukin-6 and urinary norepinephrine changes induced by sleep restriction. J Clin Endocrinol Metab 2015; 100: E416-26.
25. Moldofsky H, Lue FA, Davidson JR, Gorczynski R. Effects of sleep deprivation on human immune functions. FASEB J 1989; 3: 1972-7.
26. Dinges DF, Douglas SD, Hamarman S, Zaugg L, Kapoor S. Sleep deprivation and human immune function. Adv Neuroimmunol 1995; 5: 97-110.
27. Irwin MR, Carrillo C, Olmstead R. Sleep loss activates cellular markers of inflammation: Sex differences. Brain Behav Immun 2010; 24: 54-7.
28. Dimitrov S, Besedovsky L, Born J, Lange T. Differential acute effects of sleep on spontaneous and stimulated production of tumor necrosis factor in men. Brain Behav Immun 2015; 47: 201-10.
29. Christoffersson G, Vagesjo E, Pettersson US, et al. Acute sleep deprivation in healthy young men: Impact on population diversity and function of circulating neutrophils. Brain Behav Immun 2014; 41: 162-72.
30. Redwine L, Dang J, Irwin M. Cellular adhesion molecule expression, nocturnal sleep, and partial night sleep deprivation. Brain Behav Immun 2004; 18: 333-40.
31. Ozturk L, Pelin Z, Karadeniz D, Kaynak H, Cakar L, Gozukirmizi E. Effects of 48 hours sleep deprivation on human immune profile. Sleep Research Online 1999; 2: 107-11.
32. Seugnet L, Boero J, Gottschalk L, Duntley SP, Shaw PJ. Identification of a biomarker for sleep drive in flies and humans. Proc Natl Acad Sci U S A 2006; 103: 19913-8.
33. von Schantz M, Skene DJ. Telling biological time from a blood sample: Current capabilities and future potential. Ann Clin Biochem 2015; 52: 699-701.
34. Goel N. 'Omics' approaches for sleep and circadian rhythm research: Biomarkers for identifying differential vulnerability to sleep loss. Curr Sleep Med Rep 2015; 1: 38-46.
35. Pawlyk AC, Ferber M, Shah A, Pack AI, Naidoo N. Proteomic analysis of the effects and interactions of sleep deprivation and aging in mouse cerebral cortex. J Neurochem 2007; 103: 2301-13.
36. Naidoo N. Potential of proteomics as a bioanalytic technique for quantifying sleepiness. J Clin Sleep Med 2011; 7: S28-S30.
37. Arnardottir ES, Nikonova EV, Shockley KR, et al. Blood-gene expression reveals reduced circadian rhythmicity in individuals resistant to sleep deprivation. Sleep 2014; 37: 1589-U172.
38. Moller-Levet CS, Archer SN, Bucca G, et al. Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. Proc Natl Acad Sci U S A 2013; 110: E1132-41.
39. Davies SK, Ang JE, Revell VL, et al. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci U S A 2014; 111: 10761-6.
40. Weljie AM, Meerlo P, Goel N, et al. Oxalic acid and diacylglycerol 36: 3 are cross-species markers of sleep debt. Proc Natl Acad Sci U S A 2015; 112: 2569-74.
41. Chua EC-P, Shui G, Cazenave-Gassiot A, Wenk MR, Gooley JJ. Changes in plasma lipids during exposure to total sleep deprivation. Sleep 2015; 38: 1683-91.
42. Besedovsky L, Lange T, Born J. Sleep and immune function. Pflugers Arch 2012; 463: 121-37.
43. Bell LN, Kilkus JM, Booth JN, Bromley LE, Imperial JG, Penev PD. Effects of sleep restriction on the human plasma metabolome. Physiol Behav 2013; 122: 25-31.
44. Jackson ML, Gunzelmann G, Whitney P, et al. Deconstructing and reconstructing cognitive performance in sleep deprivation. Sleep Med Rev 2013; 17: 215-25.
45. Rupp TL, Wesensten NJ, Balkin TJ. Trait-like vulnerability to total and partial sleep loss. Sleep 2012; 35: 1163-72.
46. Michael DJ, Daugherty S, Santos A, Ruby BC, Kalns JE. Fatigue biomarker index: An objective salivary measure of fatigue level. Accid Anal Prev 2012; 45: 68-73.
47. Montesi SB, Bajwa EK, Malhotra A. Biomarkers of sleep apnea. Chest 2012; 142: 239-45.
48. Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 2006; 8: E146-52.
49. Williams CJ, Hu FB, Patel SR, Mantzoros CS. Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes. Diabetes Care 2007; 30: 1233-40.
50. Jullian-Desayes I, Joyeux-Faure M, Tamisier R, et al. Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: A systematic review from sham CPAP randomized controlled trials. Sleep Med Rev 2015; 21: 23-38.
51. Altinas N, Mutlu LC, Akkoyun DC, et al. Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea. Angiology, June 2015 [epub ahead of print].
52. Stradling JR, Schwarz EI, Schlatzer C, et al. Biomarkers of oxidative stress following continuous positive airway pressure withdrawal: Data from two randomised trials. Eur Respir J 2015; 46: 1065-71
53. Liu A, Lamendola C, Ariel D, et al. Usefulness of fetuin-A to predict risk for cardiovascular disease among patients with obstructive sleep apnea. Am J Cardiol 2015; 116: 219-24.
54. Kheirandish-Gozal L, Gileles-Hillel A, Alonso-Alvarez M, et al. Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: A community-based study. Int J Obes 2015; 39: 1094-100.
55. Canto GDL, Pacheco-Pereira C, Aydinoz S, Major PW, Flores-Mir C, Gozal D. Biomarkers associated with obstructive sleep apnea: A scoping review. Sleep Med Rev 2015; 23: 28-45.
56. de Araújo Freitas IG, de Bruin PF, Bittencourt L, de Bruin VM, Tufik S. What can blood biomarkers tell us about cardiovascular risk in obstructive sleep apnea? Sleep Breath 2015; 19: 755-68.
57. Arnardottir ES, Lim DC, Keenan BT, et al. Effects of obesity on the association between long-term sleep apnea treatment and changes in interleukin-6 levels: The Icelandic Sleep Apnea Cohort. J Sleep Res 2015; 24: 148-59.
58. De Luca Canto G, Pacheco-Pereira C, Aydinoz S, Major PW, Flores- Mir C, Gozal D. Diagnostic capability of biological markers in assessment of obstructive sleep apnea: A systematic review and metaanalysis. J Clin Sleep Med 2015; 11: 27-36.
59. Kosacka M, Brzecka A, Piesiak P, Korzeniewska A, Jankowska R. Soluble Ligand CD40 and uric acid as markers of atheromatosis in patients with obstructive sleep apnea. Inflammatory Bowel Dis 2015; 839: 55-60.
60. Maeder MT, Strobel W, Christ M, et al. Comprehensive biomarker profiling in patients with obstructive sleep apnea. Clin Biochem 2015; 48: 340-6.
61. Stradling JR, Craig S, Kohler M, Nicoll D, Ayers L, Nunn AJ. Markers of inflammation: Data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA. Thorax 2015; 70: 181.
62. Kunos L, Bikov A, Lazar Z, et al. Evening and morning exhaled volatile compound patterns are different in obstructive sleep apnoea assessed with electronic nose. Sleep Breath 2015; 19: 247-53.
63. Tan HL, Kheirandish-Gozal L, Gozal D. The promise of translational and personalised approaches for paediatric obstructive sleep apnoea: An 'Omics' perspective. Thorax 2014; 69: 450-6.
64. Gharib SA, Seiger AN, Hayes AL, Mehra R, Patel SR. Treatment of obstructive sleep apnea alters cancer-associated transcriptional signatures in circulating leukocytes. Sleep 2014; 37: 709-U309.
65. Kentsis A. Challenges and opportunities for discovery of disease biomarkers using urine proteomics. Pediatr Int 2011; 53: 1-6.
66. Zurbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012; 61: 3304-13.
67. Zimmerli LU, Schiffer E, Zurbig P, et al. Urinary proteomic biomarkers on coronary artery disease. Mol Cell Proteomics 2008; 7: 290-8.
68. Gozal D, Jortani S, Snow AB, et al. Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in pediatric obstructive sleep apnea. Am J Respir Crit Care Med 2009; 180: 1253-61.
69. Kheirandish-Gozal L, Mcmanus CJT, Kellermann GH, Samiei A, Gozal D. Urinary neurotransmitters are selectively altered in children with obstructive sleep apnea and predict cognitive morbidity. Chest 2013; 143: 1576-83.
70. Sanchez-de-la-Torre M, Khalyfa A, Sanchez-de-la-Torre A, et al. Precision medicine in patients with resistant hypertension and obstructive sleep apnea blood pressure response to continuous positive airway pressure treatment. J Am Coll Cardiol 2015; 66: 1023-32.
71. Montesi SB, Bajwa EK, Malhotra A. Biomarkers of sleep apnea. Chest 2012; 142: 239-45.
72. Thimgan MS, Toedebusch C, McLeland J, Duntley SP, Shaw PJ. Excessive daytime sleepiness is associated with changes in salivary inflammatory genes transcripts. Mediators Inflamm 2015; 2015: 539627.
73. Paik MJ, Kim DK, Nguyen DT, et al. Correlation of daytime sleepiness with urine metabolites in patients with obstructive sleep apnea. Sleep Breath 2014; 18: 517-23.
74. Uysal A, Liendo C, McCarty DE, et al. Nocturnal hypoxemia biomarker predicts sleepiness in patients with severe obstructive sleep apnea. Sleep Breath 2014; 18: 77-84.
75. Sanchez-de-la-Torre M, Barcelo A, Pierola J, et al. Plasma levels of neuropeptides and metabolic hormones, and sleepiness in obstructive sleep apnea. Respir Med 2011; 105: 1954-60.
76. Bravo MD, Serpero LD, Barcelo A, Barbe F, Agusti A, Gozal D. Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness. Sleep Breath 2007; 11: 177-85.
77. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003; 26: 342-92.
78. Marino M, Li Y, Rueschman MN, et al. Measuring sleep: Accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep 2013; 36: 1747-55.
79. Benloucif S, Burgess HJ, Klerman EB, et al. Measuring melatonin in humans. J Clin Sleep Med 2008; 4: 66-9.
80. Burgess HJ, Wyatt JK, Park M, Fogg LF. Home circadian phase assessments with measures of compliance yield accurate dim light melatonin onsets. Sleep 2015; 38: 889-97.
81. Voultsios A, Kennaway DJ, Dawson D. Salivary melatonin as a circadian phase marker: Validation and comparison to plasma melatonin. J Biol Rhythms 1997; 12: 457-66.
82. Sarabia J, Rol M, Mendiola P, Madrid J. Circadian rhythm of wrist temperature in normal-living subjects A candidate of new index of the circadian system. Physiol Behav 2008; 95: 570-80.
83. Bonmati-Carrion M, Middleton B, Revell V, Skene D, Rol M, Madrid J. Circadian phase asessment by ambulatory monitoring in humans: Correlation with dim light melatonin onset. Chronobiol Int 2014; 31: 37-51.
84. Chua EC-P, Shui G, Lee IT-G, et al. Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proc Natl Acad Sci U S A 2013; 110: 14468-73.
85. Kasukawa T, Sugimoto M, Hida A, et al. Human blood metabolite timetable indicates internal body time. Proc Natl Acad Sci U S A 2012; 109: 15036-41.
86. Gooley JJ, Chua EC. Diurnal regulation of lipid metabolism and applications of circadian lipidomics. J Genet Genomics 2014; 41: 231-50.
87. Archer SN, Laing EE, Moller-Levet CS, et al. Mistimed sleep disrupts circadian regulation of the human transcriptome. Proc Natl Acad Sci U S A 2014; 111: E682-91.
88. Laing EE, Johnston JD, Moller-Levet CS, et al. Exploiting human and mouse transcriptomic data: Identification of circadian genes and pathways influencing health. Bioessays 2015; 37: 544-56.
89. Colten HR, Altevogt BM, eds. Sleep disorders and sleep deprivation: An unmet public health problem. Washington, DC: The National Academies Press, 2006.